0001181431-11-055726.txt : 20111110 0001181431-11-055726.hdr.sgml : 20111110 20111110150151 ACCESSION NUMBER: 0001181431-11-055726 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20111110 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20111110 DATE AS OF CHANGE: 20111110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CERUS CORP CENTRAL INDEX KEY: 0001020214 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 680262011 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21937 FILM NUMBER: 111194903 BUSINESS ADDRESS: STREET 1: 2550 STANWELL DRIVE CITY: CONCORD STATE: CA ZIP: 94520 BUSINESS PHONE: 9252886000 MAIL ADDRESS: STREET 1: 2550 STANWELL DRIVE STREET 2: STE 300 CITY: CONCORD STATE: CA ZIP: 94520 FORMER COMPANY: FORMER CONFORMED NAME: CERUS TECHNOLOGIES INC DATE OF NAME CHANGE: 19960731 8-K 1 rrd325558.htm NEW SUPPLY AGREEMENT - EFS Prepared By R.R. Donnelley Financial -- Form 8-K
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):  11/10/2011
 
Cerus Corporation
(Exact name of registrant as specified in its charter)
 
Commission File Number:  0-21937
 
Delaware
  
68-0262011
(State or other jurisdiction of
  
(IRS Employer
incorporation)
  
Identification No.)
 
2550 Stanwell Drive
Concord, California 94520
(Address of principal executive offices, including zip code)
 
(925) 288-6000
(Registrant’s telephone number, including area code)
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 
Item 8.01.    Other Events
 
On November 10, 2011, Cerus Corporation (the "Company") announced that it has signed a new two-year agreement commencing November 9, 2011 with the French national blood service, the Etablissement Francais du Sang (EFS), to supply INTERCEPT Blood System disposable kits for platelets and plasma. A copy of the Company's press release, entitled "Cerus Announces New Supply Agreement with French National Blood Service," is attached hereto as Exhibit 99.1 and hereby incorporated by reference.
 
 
Item 9.01.    Financial Statements and Exhibits
 
(d)         Exhibits.
        The following exhibit is filed with this report:

        99.1        Press release, dated November 10, 2011, entitled "Cerus Announces New Supply Agreement with French National Blood Service."

 

 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
           
Cerus Corporation
 
 
Date: November 10, 2011
     
By:
 
/s/    Kevin D. Green
               
Kevin D. Green
               
Vice President, Finance and Chief Accounting Officer
 
 

 

EXHIBIT INDEX
 
Exhibit No.
  
Description
EX-99.1
  
Press release, dated November 10, 2011, entitled "Cerus Announces New Supply Agreement with French National Blood Service."
EX-99 2 rrd325558_36474.htm PRESS RELEASE, DATED NOVEMBER 10, 2011, ENTITLED "CERUS ANNOUNCES NEW SUPPLY AGREEMENT WITH FRENCH NATIONAL BLOOD SERVICE." Prepared by RR Donnelley

Exhibit 99.1

Cerus Announces New Supply Agreement with French National Blood Service

  • Two-year agreement; renewable by EFS for two additional one-year periods

  • 50,000 to 112,800 platelet kits

  • 65,000 to 285,000 plasma kits (to treat 195,000 to 855,000 plasma units)

CONCORD, Calif.--(BUSINESS WIRE) - November 10, 2011-- Cerus Corporation (NASDAQ: CERS) announced today that it has signed a new two-year agreement commencing November 9, 2011 with the French national blood service, the Etablissement Francais du Sang (EFS), to supply INTERCEPT Blood System disposable kits for platelets and plasma. The agreement calls for EFS to purchase at least 50,000 platelet kits and 65,000 plasma kits over the initial two-year period. During this period, EFS may elect to purchase additional kits, as needed, up to a maximum of 112,800 platelet kits and 285,000 plasma kits. The agreement may be renewed by EFS for up to two additional one-year periods.

"We are proud to have been chosen to continue supplying INTERCEPT to France's transfusion service, which holds itself to the highest regulatory and production standards," said William "Obi" Greenman, Cerus' president and chief executive officer. "As a result of this new supply agreement, we expect a significant increase in INTERCEPT plasma production as EFS diversifies away from production of methylene blue-treated plasma. The agreement also allows for potential growth in the use of INTERCEPT platelets."

France produces approximately 275,000 units of platelets and 380,000 units of plasma per year. INTERCEPT platelets are currently produced at four EFS blood centers representing approximately 8% of the annual platelet production. INTERCEPT plasma has historically been produced at four EFS centers representing approximately 15% of the annual plasma production, and production has recently been expanded to include five additional centers in three EFS regions. INTERCEPT is the only pathogen inactivation (PI) technology approved in France for treatment of platelets. INTERCEPT and one other PI method are approved in France for treatment of plasma. Methylene blue, a third plasma PI method, is being withdrawn by the French regulatory agency and is to be phased out by March 2012.

ABOUT CERUS
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements relating to potential growth in the use of the INTERCEPT platelet and plasma systems and to the withdrawal of methylene blue-treated plasma in France and the timing thereof. These forward-looking statements are based upon Cerus' current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with EFS demand for the INTERCEPT Blood System, including the risk that Cerus may not be able to maintain its supply agreement with EFS or that it may not be renewed, risks respecting Cerus' ability to obtain sufficient quantities of raw materials and components and to fulfill large orders on short notice, and adverse decisions or actions by regulatory agencies including Afssaps, as well as other risks detailed in the Cerus' filings with, the Securities and Exchange Commission (SEC), including in Cerus' quarterly report on Form 10-Q for the quarter ended September 30, 2011, filed with the SEC on November 3, 2011. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Cerus does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.

Contact:
Lainie Corten
Director, Global Communications & Marketing
Cerus Corporation
(925) 288-6319